Antisense Oligonucleotides against Cancer Cell Migration and Invasion
Summary:
NCI is seeking parties interested in co-developing and/or licensing therapeutic antisense oligonucleotides that target cell migration and cancer metastasis.
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Summary:
The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.
Description of Technology:
CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Summary:
The NCI is seeking licensing partners and/or collaborators to perform IND enabling studies to translate the anti-CD206 small molecule into a therapeutic for CD206 expressing cancers.
Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain
Summary:
The scientists seek co-development parties and/or licensees for a method for measuring low-abundance metabolites in vivo.
Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease
Description of Technology:
The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.
Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
Summary:
NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL).
Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
Summary:
NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs.
Use of Acetalax for Treatment of Triple Negative Breast Cancer
Summary:
NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).
Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants
Description of Technology:
Gel materials, particularly hydrogels, typically lose their mechanical strength and stiffness as they swell. This property limits their use in both biological (e.g., cartilage and ECM repair) and non-biological (e.g., sealant) applications. Innovative materials in both medical and non-medical application areas are sorely needed.
Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use
Description of Technology:
Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially difficult.